Healthcare / Diagnostics / Biotechnology
$00.00
EXAS
Exact Sciences (Nasdaq: EXAS) is a leading provider of cancer screening and diagnostic tests that helps patients and healthcare providers make informed decisions throughout the cancer care journey. The company was incorporated in 1995 and is headquartered in Madison, Wisconsin, establishing itself as a pioneer in molecular diagnostics focused on early cancer detection and prevention.
Exact Sciences operates at the forefront of molecular diagnostics, dedicated to revolutionizing cancer detection and prevention. The company's mission is to improve patient outcomes by providing accurate, accessible, and innovative screening and diagnostic solutions. Its commitment to groundbreaking research and development has positioned it as a key player in the fight against cancer.
Exact Sciences offers Cologuard, a non-invasive stool-based DNA screening test that detects DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. This flagship product has transformed colorectal cancer screening by providing patients with a convenient at-home testing option. The Cologuard test has been used more than 20 million times since 2014, demonstrating its widespread adoption and impact in clinical practice.
The company operates through two primary business segments:
- Cologuard: The company's primary colorectal cancer screening test.
- Cologuard Plus: The next-generation colon cancer screening test, designed to further improve accuracy and reduce false positives.
The company provides a suite of tests for personalized cancer care, including:
- Oncotype DX Breast Recurrence Score Test
- Oncotype DX Breast DCIS Score Test
- Oncotype DX Colon Recurrence Score Test
- OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer.
- Riskguard Test, a hereditary cancer test.
The Oncotype DX Breast Recurrence Score test is notably the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
Exact Sciences delivered record total second quarter revenue of $811 million, an increase of 16% on a reported and core revenue basis. This included Screening revenue of $628 million and Precision Oncology revenue of $183 million. This performance exceeded expectations and led to raised guidance for the full year.
In 2024, Exact Sciences's revenue reached $2.76 billion, an increase of 10.37% compared to the previous year's $2.50 billion. The company achieved total 2024 revenue with Screening revenue at $2.10 billion and Precision Oncology revenue at $655 million.
- Revenue Growth (Trailing 12 Months ending June 30, 2025): $2.940 billion, a 12.56% increase year-over-year.
- Market Position: Revenue growth has remained positive, and net income losses have narrowed significantly, indicating improving operational efficiency and financial health.
- Guidance: Raised guidance for the full fiscal year 2025, reflecting confidence in continued growth.
The company plans to launch three significant new cancer tests in 2025:
- Cologuard Plus: The next-generation colorectal cancer screening test.
- Oncodetect: A molecular residual disease (MRD) test.
- Cancerguard: A multi-cancer screening test.
With nearly 6 million cancer survivors in the U.S. who could potentially benefit from residual and recurrent disease testing, yet less than 5% currently receiving such vital testing, the Oncodetect test is positioned as a leading solution for monitoring residual disease and cancer recurrence. The company secured Medicare coverage for its Oncodetect molecular residual disease test during Q2 2025, a significant step towards broader adoption.
Exact Sciences has entered into an exclusive license agreement with Freenome for blood-based colorectal cancer screening tests, further expanding its portfolio of screening technologies and market reach.
The stock of Exact Sciences Corporation (EXAS) is well-regarded by the financial community. According to recent analyst reports:
- The average rating for EXAS stock is "Strong Buy".
- Based on 29 analysts, 89.66% of analysts recommend a 'BUY' rating for Exact Sciences Corporation.
- The average target price of $63.14 represents a potential upside of 12.26% compared to current market price levels, indicating positive analyst sentiment.
Exact Sciences anticipates accelerated growth in 2025 driven by several key factors:
- Increased adoption of Cologuard through re-screens and care gap programs.
- The highly anticipated launch of Cologuard Plus.
- Improved commercial execution and expanded market access.
While acknowledging near-term challenges, the company is confident that growth will accelerate, and margins will continue to expand. Exact Sciences targets 15% compounded revenue growth and greater than 20% adjusted EBITDA margin by 2027.
The company expects to launch the Cologuard Plus test with Medicare coverage and guideline inclusion in 2025, which is projected to drive broader patient adoption and significantly contribute to revenue growth.
To underscore the critical importance of early detection, Exact Sciences has launched prominent marketing campaigns. A notable initiative partners with actor Matthew Lillard to encourage individuals aged 45 and older to get screened for colorectal cancer, the nation's second leading cause of cancer-related death. This campaign effectively highlights that early-stage colon cancer has a 90% survival rate, emphasizing the life-saving impact of screening.
Exact Sciences continues to solidify its position as a leader in cancer diagnostics through continuous innovation, strategic partnerships, and the expansion of market access for its life-saving tests, positioning the company for sustained growth in the dynamic precision medicine market.
Clients/Investors to abstain them from dealing in any schemes of unauthorised collective investments / portfolio management, indicative/ guaranteed/fixed returns / payments etc.
Sr. No
Name of KMP
Designation
Mobile Number
Email ID
2.
Mr. Amit Bansal
Designated Director /
Compliance Officer